Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis
(2000) In Alimentary pharmacology & therapeutics 14(9). p.62-1159- Abstract
BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).
METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.
RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively... (More)
BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).
METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.
RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.
CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.
(Less)
- author
- Järnerot, G ; Ström, M ; Danielsson, A ; Kilander, A ; Lööf, L ; Hultcrantz, R ; Löfberg, R ; Florén, C LU ; Nilsson, A LU and Broström, O
- publishing date
- 2000-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Aged, Allopurinol/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antimetabolites/administration & dosage, Colitis, Ulcerative/drug therapy, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Mesalamine/administration & dosage, Middle Aged, Recurrence, Sweden
- in
- Alimentary pharmacology & therapeutics
- volume
- 14
- issue
- 9
- pages
- 4 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:10971232
- scopus:0033806902
- ISSN
- 0269-2813
- DOI
- 10.1046/j.1365-2036.2000.00821.x
- language
- English
- LU publication?
- no
- id
- df5bd628-36cf-445e-b8e0-8da03923808e
- date added to LUP
- 2019-09-19 14:40:48
- date last changed
- 2023-01-08 04:29:33
@article{df5bd628-36cf-445e-b8e0-8da03923808e,
abstract = {{<p>BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).</p><p>METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.</p><p>RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.</p><p>CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.</p>}},
author = {{Järnerot, G and Ström, M and Danielsson, A and Kilander, A and Lööf, L and Hultcrantz, R and Löfberg, R and Florén, C and Nilsson, A and Broström, O}},
issn = {{0269-2813}},
keywords = {{Adult; Aged; Allopurinol/administration & dosage; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Antimetabolites/administration & dosage; Colitis, Ulcerative/drug therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mesalamine/administration & dosage; Middle Aged; Recurrence; Sweden}},
language = {{eng}},
number = {{9}},
pages = {{62--1159}},
publisher = {{Wiley-Blackwell}},
series = {{Alimentary pharmacology & therapeutics}},
title = {{Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis}},
url = {{http://dx.doi.org/10.1046/j.1365-2036.2000.00821.x}},
doi = {{10.1046/j.1365-2036.2000.00821.x}},
volume = {{14}},
year = {{2000}},
}